Reid Alexander Waldman
Known title: Chief Executive OfficerCIK: 0002107415
Associated companies
Transaction History
| MANE | ▲ Buy | Option Exercise | 3,452 | $42K | 8/17/2026 | View on chart |
| MANE | ▼ Sell | Open Market | 25,234 | $2.7M | 8/17/2026 | View on chart |
| MANE | ▼ Sell | Open Market | 11,527 | $1.2M | 8/17/2026 | View on chart |
| MANE | ▼ Sell | Open Market | 27,490 | $3.0M | 8/17/2026 | View on chart |
| MANE | ▼ Sell | Open Market | 3,000 | $328K | 8/17/2026 | View on chart |
| MANE | ▼ Sell | Open Market | 249 | $28K | 8/17/2026 | View on chart |
| MANE | ▼ Sell | Other | 1,437 | — | 2/5/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Veradermics Momentum Builds, But H2 2026 Readouts Caution
Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.
Veradermics Momentum Builds, But H2 2026 Readouts Caution. Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.